<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1403</article-id><article-id pub-id-type="doi">10.36691/RJA1403</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Patient management plan for sublingual allergen specific immunotherapy with birch pollen allergen and the maintenance of patient compliance</article-title><trans-title-group xml:lang="ru"><trans-title>План ведения пациентов, получающих сублингвальную аллерген-специфическую терапию аллергеном пыльцы березы, и поддержание комплаентности пациентов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0854-1536</contrib-id><name-alternatives><name xml:lang="en"><surname>Trusova</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Трусова</surname><given-names>Ольга Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>associate professor, Department of Therapy with the course on Allergy and Immunology, Pavlov First Saint Petersburg Medical University, MD, PhD</p></bio><bio xml:lang="ru"><p>доцент кафедры терапии госпитальной с курсом аллергологии и иммунологии имени академика Черноруцкого с клиникой, Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, кандидат медицинских наук, доцент</p></bio><email>o-tru@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9654-3429</contrib-id><name-alternatives><name xml:lang="en"><surname>Kamaev</surname><given-names>Andrey V.</given-names></name><name xml:lang="ru"><surname>Камаев</surname><given-names>Андрей Вячеславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>associate professor, Department of General Practice (Family Medicine), Pavlov First Saint Petersburg Medical University, MD, PhD</p></bio><bio xml:lang="ru"><p>доцент кафедры общей врачебной практики (семейной медицины), Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, кандидат медицинских наук, доцент</p></bio><email>andykkam@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4740-880X</contrib-id><name-alternatives><name xml:lang="en"><surname>Makarova</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Макарова</surname><given-names>Ирина Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>associate professor, Department of Therapy with the course on Allergy and Immunology, Pavlov First Saint Petersburg Medical University, MD, PhD</p></bio><bio xml:lang="ru"><p>доцент кафедры терапии госпитальной с курсом аллергологии и иммунологии имени академика Черноруцкого с клиникой, Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, кандидат медицинских наук, доцент</p></bio><email>allergist_PI@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pavlov First Saint Petersburg Medical University</institution></aff><aff><institution xml:lang="ru">Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-10-29" publication-format="electronic"><day>29</day><month>10</month><year>2020</year></pub-date><volume>17</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>64</fpage><lpage>73</lpage><history><date date-type="received" iso-8601-date="2020-10-27"><day>27</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-10-27"><day>27</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Фармарус Принт Медиа</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2022-10-29"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/1403">https://rusalljournal.ru/raj/article/view/1403</self-uri><abstract xml:lang="en"><p>BACKGROUND: Sublingual allergen­-specific immunotherapy (SLIT) inefficiencie is mainly caused by non-­compliance with the treatment regimen and premature treatment termination.</p> <p>AIM: Frequency and causes of dropouts determination in children receiving SLIT with birch pollen according to the pre­-coseasonal protocol, and approbation of the developed visit-­to-­visit patient management plan (Plan).</p> <p>MATERIALS AND METHODS: 332 cases of treatment with birch pollen in children are analyzed. 290 patients (72.1% boys, aged 5–18 years (9.82 years [5.93; 14.67]), received SLIT with birch pollen in 2012–2019. 42 patients received SLIT according to the Plan (69% boys, 8.95 years old [5.38; 11.79]) in 2017–2019.</p> <p>RESULTS: A low dropout frequency was noted in the 1st and 2nd year of therapy (2 years after the start of treatment, 85% patients continue it). However, only 63.1% complete 3 years of therapy, and 11% ­– 4 years of therapy. It has been shown that experienced allergists have more efficient patient retention. The implementation of the Plan increased patient retention in treatment at the 3<sup>rd</sup> year of treatment up to 82.9% (p=0.02).</p> <p>CONCLUSION: The study confirmed the main reasons for the withdrawal of patients from SLIT: doubts about the effectiveness, cost and side effects. A low dropout frequency was shown according to the results of the 1<sup>st</sup> and 2<sup>nd</sup> years of therapy, but only a small proportion of patients (11%) receive 4 or more courses of therapy. Visit-­to-­visit Plan optimizes the patient’s management, reduces patients’ withdrawal from treatment and can be recommended for practical healthcare.</p></abstract><trans-abstract xml:lang="ru"><p><bold>ВВЕДЕНИЕ:</bold> К недостаточному эффекту сублингвальной аллерген-специфической иммунотерапии (слАСИТ) приводит в первую очередь несоблюдение режима лечения и преждевременное прекращение лечения.</p> <p><bold>ЦЕЛЬ:</bold> Определение частоты выбывания пациентов при проведении слАСИТ пыльцой березы по предсезонно-сезонному протоколу у детей и проведение анализа причин досрочного прерывания терапии, а также апробация повизитного Плана ведения пациента.</p> <p><bold>МАТЕРИАЛЫ И МЕТОДЫ:</bold> Проанализировано 332 случая проведения слАСИТ пыльцой березы у детей. У 290 пациентов (72,1% мальчики) в возрасте 5–18 лет (9,82 года [5,93; 14,67]) проведена слАСИТ пыльцой березы в 2012–2019 гг. 42 пациента получали в 2017–2019 гг. слАСИТ в соответствии с Планом (69% мальчики), возраст 8,95 года [5,38; 11,79].</p> <p><bold>РЕЗУЛЬТАТЫ:</bold> Отмечена низкая частота выбывания с лечения в 1-йи 2-й год терапии (через 2 года от начала лечения 85% пациентов продолжают его). Однако лишь 63,1% завершают 3 года терапии, и 11% – 4 года терапии. Показана бóльшая эффективность сохранения пациентов у опытных аллергологов. Внедрение Плана повысило удержание пациентов в лечении на 3-м году лечения до 82,9% (р=0,02).</p> <p><bold>ЗАКЛЮЧЕНИЕ:</bold> Подтверждены основные причины выбывания пациентов с лечения: сомнения в эффективности, стоимость и побочные действия. Показана низкая частота выбывания пациентов с лечения слАСИТ пыльцой березы по результатам 1 и 2 лет терапии, но лишь небольшая доля пациентов (11%) получает 4 и более курсов терапии. Повизитный план оптимизирует график ведения пациента на слАСИТ пыльцой березы; позволяет снизить выбывание пациентов с лечения и может быть рекомендован для практического здравоохранения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>allergen¬specific immunotherapy</kwd><kwd>allergic rhinitis</kwd><kwd>bronchial asthma</kwd><kwd>compliance</kwd><kwd>children</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аллерген-специфическая иммунотерапия</kwd><kwd>аллергический ринит</kwd><kwd>бронхиальная астма</kwd><kwd>комплаенс</kwd><kwd>дети</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">ginasthma.org [Internet]. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018 [cited 2018 Dec 10]. Available from: https://ginasthma.org/</mixed-citation><mixed-citation xml:lang="ru">ginasthma.org [Internet]. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018 [дата обращения: 10.12.2018]. Доступ по ссылке: https://ginasthma.org/</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. doi: 10.1111/j.1398-9995.2007.01620.x</mixed-citation><mixed-citation xml:lang="ru">Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) // Allergy. 2008. Vol. 63. Suppl 86. P. 8–160. doi: 10.1111/j.1398-9995.2007.01620.x</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Ziselson AD. Pollinoz u detei. Leningrad: Meditsina; 1989. 160 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Зисельсон А.Д. Поллиноз у детей. Ленинград : Медицина, 1989. 160 c.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Federal’nye klinicheskie rekomendatsii po provedeniyu allergen-spetsificheskoi immunoterapii [Internet]. 2013 [cited 2018 Dec 10]. Available from: https://raaci.ru/ (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Федеральные клинические рекомендации по проведению аллерген-специфической иммунотерапии [интернет]. 2013 [дата обращения: 10.12.2018]. Доступ по ссылке: https://raaci.ru/</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798. doi: 10.1111/all.13317</mixed-citation><mixed-citation xml:lang="ru">Roberts G., Pfaar O., Akdis C.A., Ansotegui I.J., Durham S.R., Gerth van Wijk R., et al. EAACI Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis // Allergy. 2018. Vol. 73. N 4. P. 765–798. doi: 10.1111/all.13317</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72(12):1825–1848. doi: 10.1111/all.13208</mixed-citation><mixed-citation xml:lang="ru">Dhami S., Kakourou A., Asamoah F., Agache I., Lau S., Jutel M., et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis // Allergy. 2017. Vol. 72. N 12. P. 1825–1848. doi: 10.1111/all.13208</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597–1631. doi: 10.1111/all.13201</mixed-citation><mixed-citation xml:lang="ru">Dhami S., Nurmatov U., Arasi S., Khan T., Asaria M., Zaman H., et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis // Allergy. 2017. Vol. 72. N 11. P. 1597–1631. doi: 10.1111/all.13201</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Nam YH, Lee SK. Physician’s recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy. Patient Prefer Adherence. 2017;11:381–387. doi: 10.2147/PPA.S118368</mixed-citation><mixed-citation xml:lang="ru">Nam Y.H., Lee S.K. Physician’s recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy // Patient Prefer Adherence. 2017. Vol. 11. P. 381–387. doi: 10.2147/PPA.S118368</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Makatsori M, Scadding GW, Lombardo C, Bisoffi G, Ridolo E, Durham SR, et al. Dropouts in sublingual allergen immunotherapy trials – a systematic review. Allergy. 2014;69(5):571–580. doi: 10.1111/all.12385</mixed-citation><mixed-citation xml:lang="ru">Makatsori M., Scadding G.W., Lombardo C., Bisoffi G., Ridolo E., Durham S.R., et al. Dropouts in sublingual allergen immunotherapy trials – a systematic review // Allergy. 2014. Vol. 69. N 5. P. 571–580. doi: 10.1111/all.12385</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy. 2013;68(9):1193–1195. doi: 10.1111/all.12198</mixed-citation><mixed-citation xml:lang="ru">Savi E., Peveri S., Senna G., Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach // Allergy. 2013. Vol. 68. N 9. P. 1193–1195. doi: 10.1111/all.12198</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol. 2010;126(3):668–669. doi: 10.1016/j.jaci.2010.06.045</mixed-citation><mixed-citation xml:lang="ru">Senna G., Lombardi C., Canonica G.W., Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint // J Allergy Clin Immunol. 2010. Vol. 126. N 3. P. 668–669. doi: 10.1016/j.jaci.2010.06.045</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Kiel MA, Röder E, van Wijk RG, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–360. doi: 10.1016/j.jaci.2013.03.013</mixed-citation><mixed-citation xml:lang="ru">Kiel M.A., Röder E., van Wijk R.G., Al M.J., Hop W.C., Rutten-van Mölken M.P. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy // J Allergy Clin Immunol. 2013. Vol. 132. N 2. P. 353–360. doi: 10.1016/j.jaci.2013.03.013</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy. 2010;65(5):668–669. doi: 10.1111/j.1398-9995.2009.02223.x</mixed-citation><mixed-citation xml:lang="ru">Vita D., Caminiti L., Ruggeri P., Pajno G.B. Sublingual immunotherapy: adherence based on timing and monitoring control visits // Allergy. 2010. Vol. 65. N 5. P. 668–669. doi: 10.1111/j.1398-9995.2009.02223.x</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Scurati S, Frati F, Passalacqua G, Puccinelli P, Hilaire C, Incorvaia C. Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Prefer Adherence. 2010;4:141–145. doi: 10.2147/ppa.s10217</mixed-citation><mixed-citation xml:lang="ru">Scurati S., Frati F., Passalacqua G., Puccinelli P., Hilaire C., Incorvaia C. Adherence issues related to sublingual immunotherapy as perceived by allergists // Patient Prefer Adherence. 2010. Vol. 4. P. 141–145. doi: 10.2147/ppa.s10217</mixed-citation></citation-alternatives></ref></ref-list></back></article>
